New drug LAD191 tested for safety in autoimmune patients
NCT ID NCT06488209
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested the safety and tolerability of a new drug called LAD191 in 69 healthy adults and people with an autoimmune disease. Researchers gave single or multiple doses to see how the body processes the drug and if it causes side effects. The goal was to gather initial safety data, not to treat the disease. This is a first step before larger studies can explore whether LAD191 might help control autoimmune conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Doral Medical Research
Miami, Florida, 33165, United States
-
ICON Early Phase Services, LLC
San Antonio, Texas, 78209, United States
-
Jennifer Parish, MD
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults